Some of the factors driving the growth of the precision medicine market are the increased approval of drugs with companion diagnostic assays, cost-effective DNA profiling, rising cancer incidence rates, and the advent of data-driven healthcare. Furthermore, the growing use of “multi-omics” in research, as well as the penetration of high-throughput sequencing systems, is influencing the precision medicine landscape. In oncology, the number of targeted compounds in development for a given use has been expanding at an exponential rate.
The desire for a personalized product has grown as the cost of drug discovery has risen in tandem with regulatory restrictions. Companion diagnostics appear to provide a set of tools as well as pertinent clinical and biological information.
Read more @ https://bit.ly/3In9tLf